Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis

References

• GelfandJMGladmanDDMeasePJEpidemiology of psoriatic arthritis in the population of the United StatesJ Am Acad Dermatol20055357357716198775
   PubMed Web of Science ®Google Scholar
• IbrahimGWaxmanRHelliwellPSThe prevalence of psoriatic arthritis in people with psoriasisArthritis Rheum200961101373137819790120
   PubMed Web of Science ®Google Scholar
• GottliebAKormanNJGordonKBGuidelines of care for the management of psoriasis and psoriatic arthritis, Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsJ Amer Acad Dermatol20085885186418423261
   PubMed Web of Science ®Google Scholar
• AntoniCKruegerGGde VlamKInfliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 TrialAnn Rheum Dis2005641150115715677701
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXEtanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progressionArthritis Rheum20045072264227215248226
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-lind, randomized, placebo-controlled trialArthritis Rheum200552103279328916200601
   PubMed Web of Science ®Google Scholar
• Centocor IncSimponi (golimumab): Product insert (US) [online]. From Drugs@FDA Accessed Apr 26 2010. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s000lbl.pdf
   Google Scholar
• TraceyDKlareskogLSassoESalfeldJTakPTumor necrosis factor antagonist mechanism of action: a comprehensive reviewPharmacol Ther200811724427918155297
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritisArthritis Rheum200960497698619333944
   PubMed Web of Science ®Google Scholar
• InmanRDavisJCvan der HeijdeDEfficacy and safety of golimumab in patients with ankylosing spondylitisArthritis Rheum200858113402341218975305
   PubMed Web of Science ®Google Scholar
• KayJMattesonEJDasguptaBGolimumab in patients with active rheumatoid arthritis despite treatment with methotrexateArthritis Rheum200858496497518383539
   PubMed Web of Science ®Google Scholar
• XuZVuTLeeHPopulation pharmacokinetics of golimumab, an anti-tumor necrosis factor-α human monoclonal antibody, in patients with psoriatic arthritisJ Clin Pharmacol2009491056107019617465
   PubMed Web of Science ®Google Scholar
• KavanaughAMeasePKruegerGGGolimumab, a new human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL studyAbstract presented at the 2009 European League Against Rheumatism (EULAR) Annual CongressJun 10–13Copenhagen
   Google Scholar
• KavanaughAvan der HeijdeDGladmanDGolimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results From the GO-REVEAL studyAbstract presented at the 2009 ACR/ARHP Annual Scientific MeetingOct 17–21Philadelphia
   Google Scholar
• SmolenJSKayJDoyleMKGolimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomized, double-blind, placebo-controlled, phase III trialLancet200937421022119560810
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCKlareskogLGolimumab, a human antibody to tumor necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnn Rheum Dis20096878979619066176
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRMMorelandLWGolimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritisArthritis Rheum20096082272228319644849
   PubMed Web of Science ®Google Scholar
• BaecklundEIliadouAAsklingJAssociation of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis Rheum200654369270116508929
   PubMed Web of Science ®Google Scholar
• ChungEPackerMLoKHFasanmadeAAWillersonJTRandomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failureCirculation20091073133314012796126
   PubMed Web of Science ®Google Scholar
• KerbleskiJFGottliebABDermatological complications and safety of anti-TNF treatmentsGut20095881033103919592682
   PubMed Web of Science ®Google Scholar
• The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupTNF neutralization in MS: results of a randomized, placebo-controlled multicenter studyNeurology199953345746510449104
   PubMed Web of Science ®Google Scholar
• SicotteNLVoskuhlRROnset of multiple sclerosis associated with anti-TNF therapyNeurology2001571885188811723281
   PubMed Web of Science ®Google Scholar
• FrankelAJVan VoorheesASHsuSKormanNJLebwohlMGBeboBFfor the National Psoriasis FoundationTreatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis FoundationJ Amer Acad Dermatol2009In press.
   Web of Science ®Google Scholar
• Centocor, IncRemicade® (infliximab): Product insert (US) [online]. From Drugs@FDA Accessed Apr 26, 2010. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf
   Google Scholar
• Immunex CorporationEnbrel® (etanercept): Product insert (US) [online]. From Drugs@FDA Accessed Apr 26, 2010. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf
   Google Scholar
• Abbott LaboratoriesHumira® (adalimumab): Product insert (US) [online]. From Drugs@FDA Accessed Apr 26, 2010. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf
   Google Scholar